Published on October 14, 2016
“I recently changed from crizotinib (Xalkori) to alectinib (Alecensa). Should I assume new therapies will bring on new side effects? What do we know about the side effects of newer therapies?” Sandi asked this question of Dr. Ross Camidge in our Ask the Expert series. Dr. Camidge, of the University of Colorado, Denver, responds to Sandi’s question with information about class-specific therapies, as well as explaining the knowledge-base differences between FDA-approved therapies versus those still in clinical trial.